EZH2 regulates expression of p57 and contributes to progression of ovarian cancer in vitro and in vivo

Cancer Science

Volumn 102, Issue 3, 2011, Pages 530-539

  Guo, Jianfeng ^a   Cai, Jing ^a   Yu, Lili ^a   Tang, Huijuan ^a   Chen, Chunyan ^a   Wang, Zehua ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROTEIN P27; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR EZH2;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER GROWTH; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; FEDERATION OF GYNECOLOGY AND OBSTETRICS; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MEDICAL SOCIETY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; NUDE MOUSE; OVARY CANCER; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ADULT; AGED; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P57; DISEASE PROGRESSION; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; OVARY; TRANSCRIPTION FACTORS;

EID: 79951723134     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01836.x     Document Type: Article

References (28)

1. Moss C, Kaye SB. Ovarian cancer: progress and continuing controversies in management. Eur J Cancer 2002; 38: 1701-7.
2. Zheng YG, Wu J, Chen Z, Goodman M. Chemical regulation of epigenetic modifications: opportunities for new cancer therapy. Med Res Rev 2008; 28: 645-87.
3. Cao R, Zhang Y. The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr Opin Genet Dev 2004; 14: 155-64.
4. Jacobs JJ, van Lohuizen M. Polycomb repression: from cellular memory to cellular proliferation and cancer. Biochim Biophys Acta 2002; 1602: 151-61.
5. Varambally S, Dhanasekaran SM, Zhou M et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002; 419: 624-9.
6. Bachmann IM, Halvorsen OJ, Collett K et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 2006; 24: 268-73.
7. Hsieh JT. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Urol Oncol 2006; 24: 566-7.
8. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 2003; 22: 5323-35.
9. Visser HP, Gunster MJ, Kluin-Nelemans HC et al. The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. Br J Haematol 2001; 112: 950-8.
10. Tang X, Milyavsky M, Shats I, Erez N, Goldfinger N, Rotter V. Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene 2004; 23: 5759-69.
11. Li Y, Nagai H, Ohno T, Yuge M, Hatano S. Aberrant DNA methylation of p57(KIP2) gene in the promoter region in lymphoid malignancies of B-cell phenotype. Blood 2002; 100: 2572-7.
12. Yang X, Karuturi RKM, Sun F, Aau M, Yu K. CDKN1C (p57KIP2) Is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells. PLoS ONE 2009; doi.
13. Lu C, Bonome T, Li Y et al. Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res 2007; 67: 1757-68.
14. Hu S, Yu L, Li Z et al. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo. Cancer Biol Ther 2010; 10: 81-8.
15. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402-8.
16. Kondo Y. Epigenetic cross-talk between DNA methylation and histone modification in human cancers. Yonsei Med J 2009; 50: 455-63.
17. Ougolkov AV, Bilim VN, Billadeau DD. Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase EZH2. Clin Cancer Res 2008; 14: 6790-6.
18. Matsukawa Y, Semba S, Kato H, Ito A, Yanagihara K, Yokozaki H. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci 2006; 97: 484-91.
19. Kleer CG, Cao Q, Varambally S et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 2003; 100: 11606-11.
20. Pateras IS, Apostolopoulou K, Koutsami M, Evangelou K, Tsantoulis P. Downregulation of the KIP family members p27(KIP1) and p57(KIP2) by SKP2 and the role of methylation in p57(KIP2) inactivation in nonsmall cell lung cancer. Int J Cancer 2006; 119: 2546-56.
21. Epping MT, Wang L, Edel MJ, Carlee L, Hernandez M, Bernards R. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell 2005; 122: 835-47.
22. Kotake Y, Cao R, Viatour P, Sage J, Zhang Y, Xiong Y. pRB family proteins are required for H3K27 trimethylation and Polycomb repression complexes binding to and silencing p16INK4a tumor suppressor gene. Genes Dev 2007; 21: 49-54.
23. Rao Z-Y, Cai M-Y, Yang G-F et al. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-b1 and is a predictor of outcome in ovarian carcinoma patients. Carcinogenesis 2010; 31: 1576-83.
24. Varambally S, Cao Q, Mani RS et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008; 32: 1695-9.
25. Friedman JM, Liang G, Liu CC et al. The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res 2009; 69: 2623-9.
26. Friedman JM, Jones PA, Liang G. The tumor suppressor microRNA-101 becomes an epigenetic player by targeting the polycomb group protein EZH2 in cancer. Cell Cycle 2009; 8: 2313-4.
27. Acharyya S, Sharma SM, Cheng AS et al. TNF inhibits Notch-1 in skeletal muscle cells by Ezh2 and DNA methylation mediated repression: implications in duchenne muscular dystrophy. PLoS ONE 2010 doi.
28. Kalashnikova EV, Revenko AS, Gemo AT et al. ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2. Cancer Res 2010 doi.